ArticlePloS one2020

Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics.

Richard L Cullum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.